Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises J&J on Acquisition of RespiVert

June 1, 2010

NEW YORK, June 1, 2010 — Centocor Ortho Biotech Inc., a subsidiary of Johnson & Johnson, announced today that it has acquired UK-based RespiVert. Covington & Burling LLP advised Johnson & Johnson on the deal.

Johnson & Johnson embraces research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. RespiVert is a molecule drug discovery company working towards the identification of new treatments for patients with Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and severe asthma.

The Covington corporate team was led by partner J. D. Weinberg in New York, with San Francisco-based associate Donald Saelinger*. Also advising on the transaction from London were partners Louise Nash and John Rupp, of counsel Peter Cooke, associates Brett Hopcroft and Robin Blaney, and trainee-solicitor Ben Sautelle-Smith.

*Admitted to the New York bar; not admitted to practice in California.

Share this article: